The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution.
Thachil
Jecko
J
Jadhav
Vittal
V
Gautam
Manish
M
McKew
Steve
S
Arumainathan
Arvind
A
Collins
Daniel
D
Smyth
Colin
C
Harper
Janice
J
Pettitt
Andrew
A
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016516:CD4-CD8 Ratio; D006801:Humans; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy / Q000276:immunology; D012507:Sarcoidosis / Q000209:etiology* / Q000276:immunology; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab